A prospective, open label, single arm, historical control trial of tocilizumab with corticosteroids in patients with microscopic polyangiitis
Phase 3
- Conditions
- Microscopic polyangiitis
- Registration Number
- JPRN-UMIN000012072
- Lead Sponsor
- Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who are prohibited to use tocilizumab by the JCR guideline for proper tocilizumab use 2) Patients who are thought to be inappropriate for tocilizumab by their attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of major clinical signs and symptoms at week 24. (MPO-ANCA or PR3-ANCA, serum CRP and ESR, BVAS2003, VDI)
- Secondary Outcome Measures
Name Time Method Improvement of major clinical signs and symptoms at week 52. Relapse rate at week 104.